Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC)

Allendorf, Daniel J.; Bordoni, Rodolfo; Grant, Stefan C.; Saleh, Mansoor N.; Reddy, Vishnu; Jerome, Mary; Dixon, Pamela M.; Miley, Deborah; Singh, Karan P.; Robert, Francisco

doi:10.1007/s00280-015-2869-6

Cited by 1 publication

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its morbidity is increasing in multiple countries (1). At present, the treatment options for patients with lung cancer include surgery, radiotherapy, and chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Epidermal growth factor receptor expression affects proliferation and apoptosis in non-small cell lung cancer cells via the extracellular signal-regulated kinase/microRNA 200a signaling pathway

Zhou

Wang

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

Abstract. The present study assessed the function of epidermal growth factor receptor (EGFR) and its molecular targets in non-small cell lung cancer. The results of the present study demonstrated that EGFR protein and mRNA expression in the normal adjacent tissue specimens was decreased compared with that in the lung cancer tissue samples. Compared with the BEAS-2B normal bronchial epithelial cells, EGFR and phosphorylated (p)-extracellular signal-regulated kinase (ERK) protein expression in the SW-900 and A549 lung cancer cells was increased and microRNA (miR)200a expression in the SW-900 and A549 cells was inhibited compared with the BEAS-2B cells. Downregulating miR200a expression significantly suppressed proliferation and promoted apoptosis and caspase (CASP)3 and CASP9 function in the A549 cells and significantly inhibited EGFR and p-ERK protein expression in the A549 cells, compared with the BEAS-2B cells. The results of the present study indicated that downregulating miR200a significantly suppressed proliferation and promoted apoptosis in A549 cells via the regulation of the EGFR and ERK 1/2 signaling pathways. IntroductionLung cancer is a malignant tumor that threatens human health and life, and exhibited the highest global occurrence rate and lethality among all types of cancer in 2012 (1). Its morbidity is increasing in multiple countries (1). At present, the treatment options for patients with lung cancer include surgery, radiotherapy, and chemotherapy. In non-small cell lung cancer (NSCLC), the typical first choice of therapy is operative treatment but, once NSCLC has been definitively diagnosed, surgery is not possible in 75% of patients since lesions have already developed, or the state of their health following surgery would potentially be poorer compared with that prior to surgery (2). Therefore, the patient may opt for chemotherapy. Though chemotherapy may decrease the recurrence rate of NSCLC in patients, only ~30% of patients with NSCLC undergo effective treatment with platinum-based first-line chemotherapy, and chemotherapy resistance is common (3). Furthermore, the 5-year survival rate for patients with NSCLC is only 15% (4). Previous research has indicated that, although novel chemotherapeutics have improved the curative effect in patients with transfer NSCLC, the associated median survival time remains only 8-9 months (5). Therefore, it is crucial to understand the occurrence and development of lung cancer, identify the molecular mechanisms underlying metastasis, and develop effective treatments for patients with malignant lung tumors.The epidermal growth factor receptor (EGFR) family, also known as the Erb-b2 receptor tyrosine kinases (ERBB), includes four main members: EGFR, ERBB2, ERBB3 and ERBB4. The EGFR family members are allosteric enzymes located at the cell surface (3). The members may be divided into three areas: A ligand-coupling domain that protrudes out of the cytomembrane, an intramembrane tyrosine kinase-activated functional domain and a transmembrane domain. The EGFR family...

show abstract

“…Its morbidity is increasing in multiple countries (1). At present, the treatment options for patients with lung cancer include surgery, radiotherapy, and chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

“…Lung cancer is a malignant tumor that threatens human health and life, and exhibited the highest global occurrence rate and lethality among all types of cancer in 2012 (1). Its morbidity is increasing in multiple countries (1).…”

Section: Introductionmentioning

confidence: 99%

Epidermal growth factor receptor expression affects proliferation and apoptosis in non-small cell lung cancer cells via the extracellular signal-regulated kinase/microRNA 200a signaling pathway

Zhou

Wang

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

show abstract

Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC)

Abstract: B + I is an active regimen in EDSCLC. Toxicities included two grade 5 events but were otherwise manageable. The novel sequence B + I E + C increased PFS and OS compared to historical controls. Correlative studies are conflicting regarding the mechanism of action of this novel sequence.

Cited by 1 publication

References 15 publications

Epidermal growth factor receptor expression affects proliferation and apoptosis in non-small cell lung cancer cells via the extracellular signal-regulated kinase/microRNA 200a signaling pathway

Epidermal growth factor receptor expression affects proliferation and apoptosis in non-small cell lung cancer cells via the extracellular signal-regulated kinase/microRNA 200a signaling pathway

Contact Info

Product

Resources

About